Logo

Eli Lilly to Sell Rights for its Two Antibiotics and a Manufacturing Facility to Eddingpharm in China for $375M

Share this

Eli Lilly to Sell Rights for its Two Antibiotics and a Manufacturing Facility to Eddingpharm in China for $375M

Shots:

  • Eli Lilly to receive $75M upfront & $300M on the completion of transaction. Eddingpharm to get exclusive rights for Lilly’s two antibiotics- Ceclor and Vancocin and a manufacturing facility located in China producing Ceclor. The transaction is expected to close in H2’19/H1’20
  • Additionally- all the employees at the Ceclor’s manufacturing facility will continue to work with Eddingpharm. Lilly will provide ongoing services to Eddingpharm for continuity of product supply & smooth transition of the facility
  • Ceclor & Vancocin are anti-infectives therapies used to treat bacterial infections & penicillin-resistant Staphylococcus aureus respectively. In 2004- Eli Lilly licensed Vancocin to ViroPharma- Flynn Pharma and Aspen Pharmacare in the US- UK and Australia respectively

Ref: Eli Lilly | Image: Eli Lilly

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions